Literature DB >> 7698160

Excitatory amino acid receptor antagonist kynurenic acid attenuates rewarding potential of morphine.

A Bespalov1, M Dumpis, L Piotrovsky, E Zvartau.   

Abstract

The effect of the non-selective antagonist of excitatory amino acid receptors kynurenic acid (50, 100 and 150 mg/kg, i.p.) on morphine-derived reward was studied in rats. Kynurenic acid dose dependently blocked the acquisition of morphine conditioned place preference when injected before conditioning. The expression of the previously established conditioned behavior was also blocked by the pretreatment with kynurenic acid (at the doses which do not reduce spontaneous locomotor activity) before testing. In the control experiments we failed to find that kynurenic acid alone exerts positive place preference conditioning or aversion. Kynurenic acid also attenuated the morphine-induced facilitation of responding in the intracranial self-stimulation test, causing a decrease in response rate and an increase in threshold current intensity. This effect was observed with doses at which kynurenic acid does not affect responding in the self-stimulation test by itself.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7698160     DOI: 10.1016/0014-2999(94)00462-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  The NMDA receptor antagonist dizocilpine (MK-801) stereoselectively inhibits morphine-induced place preference conditioning in mice.

Authors:  E Del Pozo; M Barrios; J M Baeyens
Journal:  Psychopharmacology (Berl)       Date:  1996-06       Impact factor: 4.530

2.  Facilitation of memory for extinction of drug-induced conditioned reward: role of amygdala and acetylcholine.

Authors:  Jason P Schroeder; Mark G Packard
Journal:  Learn Mem       Date:  2004 Sep-Oct       Impact factor: 2.460

3.  Hypocretin-1 receptors regulate the reinforcing and reward-enhancing effects of cocaine: pharmacological and behavioral genetics evidence.

Authors:  Jonathan A Hollander; Don Pham; Christie D Fowler; Paul J Kenny
Journal:  Front Behav Neurosci       Date:  2012-07-24       Impact factor: 3.558

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.